



1807
Fleisher
6-23-94

Attorney Docket No.: E-099-89/1

Patent

GP-1807
#32 1/2
B. White
1020-94

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

MATSUI, et al.

Serial No. 07/915,884

Filed: July 20, 1992

For: TYPE α -PLATELET DERIVED GROWTH
FACTOR RECEPTOR GENE

) Examiner: Marschel, A.

) Art Unit: 1807

RECEIVED

JUL 15 1994

GROUP 1000

Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT WITH
CERTIFICATION AN PETITION FOR CONSIDERATION
UNDER 37 C.F.R. § 1.97(c)

Sir:

In accordance with 37 C.F.R. §1.56, the references listed below and on the attached form PTO-1449 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited documents are enclosed.

English-Language Documents

Hart, et al.; "Two Classes of PDGF Receptor Recognize Different Isoforms of PDGF" Science 240:1529-31 (June 10, 1988).

Kruh, et al.; "A Novel Gene Closely Related to the *abl* Proto-Oncogene" Science 234:1545-48 (Dec. 19, 1986).

King, et al.; "Amplification of a Novel v-*erbB*-Related Gene in a Human Mammary Carcinoma" Science 229: 974-76 (Sept. 6, 1985)

Foreign-Language Documents

The following foreign-language documents are being brought to the attention of the Examiner along with a concise explanation of the relevance of each document, as it is presently understood by the individual designated in 37 C.F.R. §1.56(c) most knowledgeable about the content of the information of each document:

Serial No.: 07/915,884
Filed: July 20, 1992
Applicants: Matsui, et al

No Foreign Language Documents are cited.

This information is being submitted subsequent to the earlier of the mailing of the final action or the notice of allowance, but before payment of the issue fee. Accordingly, pursuant to 37 C.F.R. §1.97(c), the undersigned submits the following certification:

Certification under 37 C.F.R. §1.97 (e)

The undersigned hereby certifies:

 X that each item of information contained in this statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement, or

 that to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in this statement was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this statement.


It is believed that under 37 C.F.R. §1.97(c) no fee or petition is required. In the event that the Patent and Trademark Office determines that any fee and/or petition are required the undersigned hereby petitions that the Examiner consider the information cited in this Statement. Please charge my deposit account, 14-1052 the fee for the filing of the IDS under 37 C.F. R. 1.17(p) of \$200 and the petition fee of \$130 under 37 C.F.R. §1.17(i)(1). If any additional fee is required, or to credit any overpayment, please use deposit account No. 14-1052.

It is respectfully requested that the Examiner indicated consideration of the cited references by returning a copy of the attached form PTO-1559 with initials or other appropriate marks.

Dated: July 8, 1994

Office of Technology Transfer
National Institutes of Health
Box OTT
Bethesda, MD 20892-0092
Phone: (301)496-7056, ext. 245
Fax: (301)402-0220

Respectfully Submitted,



Susan S. Rucker
Attorney for Applicant(s)
Reg. No. 35,762

Serial No.: 07/915,884
Filed: July 20, 1992
Applicants: Matsui, et al

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231 on July 8, 1994.

Susan S. Rucker  Date: July 8, 1994